Core Business
Nutritional Health And Agribiotechnology
Glac Biotech Co., Ltd.
Glac Biotech has been dedicated to the field of functional probiotics and postbiotics for many years.
We adhere to the business philosophy of "Science, Quality, Sincerity, and Uniqueness" and implement quality and safety guarantees throughout the entire industry chain to create our business core value.
We provide customers with one-stop, vertically integrated solutions.
Glac also offers contract manufacturing service to tailor the production conditions for customized probiotic products.
Taiwan
Investment time | 2008 |
Incubation Successes | Center Ventures not only provided practical advice on operational focus, repositioning, strategic planning, and organizational culture but also introduced strategic partnership opportunities. It shared industry resources and supported corporate decisions for the integration of Glac Biotech and Glory Biotech to expand the business scale as well as to advance competitive advantages simultaneously. |
Milestones |
|
Date | Title | |
2023-06-28 | 晟德進軍國際益生菌市場 子公司豐華生物科技攜手韓國Nutrione 開創韓國保健品市場 | Detail |
2023-09-28 | 晟德子公司豐華生技「Totipro 益萃質®PE0401」榮獲保健食品界奧斯卡Nutra Ingredients-Asia Award: Microbiome Modulation(微生物領域)大獎 | Detail |
2023-12-05 | 晟德法說》釋「長線」佳音 展望明年景氣持樂觀看法 | Detail |
2024-04-22 | 晟德大藥廠股份有限公司(上櫃股票代號4123)發行新股為對價 受讓Bioflag International Corporation (Cayman) 股份案 重大訊息說明記者會 晟德取得旗下豐華生技100%股權 完整益生菌事業體版圖 | Detail |
2024-05-10 | 豐華生技全台首獲 FDA GRAS 認證 晉升國際級益生菌 CDMO | Detail |
2024-04-01 | [先探雜誌]大健康產業商機—保健品原料 | Detail |
2024-05-13 | 晟德公告第一季財報 受金融資產評價影響 每股損失0.78元 醫藥及益生菌事業穩健增長 投資事業谷底翻身 | Detail |
2024-05-31 | 豐華生技益生菌事業2024營收估破5億元 繼澳優乳業後 晟德重押大健康領域 | Detail |
2024-06-25 | 晟德股東會/承認配發1.5元現金股利 殖利率3.3% 連續24年配發股利 2024年成長充滿信心 續替股東創造最大價值 | Detail |
2024-07-19 | 林榮錦打造晟德生技投資帝國 | Detail |
2024-08-13 | 晟德(4123)Q2財報新聞稿 | Detail |